Processa Pharmaceuticals, Inc.
PCSA
$1.99
-$0.17-7.87%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.62M | 6.44M | 6.18M | 5.61M | 4.92M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.86M | 14.47M | 13.99M | 13.02M | 12.96M |
| Operating Income | -12.86M | -14.47M | -13.99M | -13.02M | -12.96M |
| Income Before Tax | -13.44M | -14.11M | -13.56M | -12.93M | -12.88M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -13.44 | -14.11 | -13.56 | -12.93 | -12.88 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.44M | -14.11M | -13.56M | -12.93M | -12.88M |
| EBIT | -12.86M | -14.47M | -13.99M | -13.02M | -12.96M |
| EBITDA | -12.86M | -14.47M | -13.99M | -13.02M | -12.96M |
| EPS Basic | -5.77 | -10.84 | -17.13 | -35.06 | -59.08 |
| Normalized Basic EPS | -3.61 | -6.78 | -10.71 | -21.91 | -36.92 |
| EPS Diluted | -5.77 | -10.84 | -17.13 | -35.06 | -59.08 |
| Normalized Diluted EPS | -3.61 | -6.78 | -10.71 | -21.91 | -36.92 |
| Average Basic Shares Outstanding | 9.53M | 7.41M | 5.16M | 3.04M | 1.27M |
| Average Diluted Shares Outstanding | 9.53M | 7.41M | 5.16M | 3.04M | 1.27M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |